Compare PLETHICO PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ABBOTT INDIA PLETHICO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x -1.1 44.7 - View Chart
P/BV x 0.0 12.8 0.1% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PLETHICO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ABBOTT INDIA
Mar-18
PLETHICO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3956,110 6.5%   
Low Rs313,996 0.8%   
Sales per share (Unadj.) Rs604.41,552.2 38.9%  
Earnings per share (Unadj.) Rs32.5188.8 17.2%  
Cash flow per share (Unadj.) Rs51.3196.4 26.1%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs473.6796.6 59.4%  
Shares outstanding (eoy) m34.0821.25 160.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.3 10.8%   
Avg P/E ratio x6.626.8 24.5%  
P/CF ratio (eoy) x4.225.7 16.1%  
Price / Book Value ratio x0.56.3 7.1%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m7,262107,376 6.8%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m1,5963,937 40.5%   
Avg. sales/employee Rs ThNM9,929.3-  
Avg. wages/employee Rs ThNM1,185.1-  
Avg. net profit/employee Rs ThNM1,207.7-  
INCOME DATA
Net Sales Rs m20,59832,985 62.4%  
Other income Rs m3861,170 33.0%   
Total revenues Rs m20,98434,155 61.4%   
Gross profit Rs m2,8185,245 53.7%  
Depreciation Rs m642162 396.7%   
Interest Rs m1,59338 4,170.7%   
Profit before tax Rs m9696,215 15.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1382,203 -6.3%   
Profit after tax Rs m1,1074,012 27.6%  
Gross profit margin %13.715.9 86.0%  
Effective tax rate %-14.335.4 -40.3%   
Net profit margin %5.412.2 44.2%  
BALANCE SHEET DATA
Current assets Rs m18,87722,655 83.3%   
Current liabilities Rs m11,8966,681 178.1%   
Net working cap to sales %33.948.4 70.0%  
Current ratio x1.63.4 46.8%  
Inventory Days Days3665 55.5%  
Debtors Days Days19829 678.6%  
Net fixed assets Rs m9,861835 1,180.2%   
Share capital Rs m341213 160.3%   
"Free" reserves Rs m12,33116,715 73.8%   
Net worth Rs m16,13916,928 95.3%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14624,162 137.2%  
Interest coverage x1.6163.7 1.0%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.61.4 45.5%   
Return on assets %8.116.8 48.6%  
Return on equity %6.923.7 28.9%  
Return on capital %12.336.9 33.3%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,402369 1,194.6%   
Fx outflow Rs m3,1843,807 83.6%   
Net fx Rs m1,219-3,438 -35.4%   
CASH FLOW
From Operations Rs m2,4371,527 159.6%  
From Investments Rs m-6,265-2,148 291.6%  
From Financial Activity Rs m2,490-1,024 -243.1%  
Net Cashflow Rs m-1,337-1,646 81.3%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 7.9 54.4%  
FIIs % 5.5 0.1 5,500.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.1 43.9%  
Shareholders   10,665 18,270 58.4%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS